Compare REX AI Equity Premium Income ETF (AIPI) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs BioNano Genomics Inc — how do they compare? REX AI Equity Premium Income ETF trades at $36.23, while BioNano Genomics Inc trades at $1.14 (market cap $13.08M). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AIPI | BNGO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $4.92 |
52-Week Low | $32.45 | $1.09 |
Market Cap | — | $13.08M |
Enterprise Value | — | $15.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
BNGO trades at $1.14, down 0.87% on the day, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported Q1 2026 revenue of $28.51M and a net loss of $26.40M, though it beat EPS estimates. Recent news includes leadership changes, debt retirement, and growing adoption of its optical genome mapping technology. Valuation ratios appear low with a P/E of 0.03 and P/S of 0.3, but profitability remains negative.
Outlook is cautiously optimistic due to improving cash flow trends and analyst support, but significant risks persist from ongoing losses and competitive pressures. The stock's near-term direction hinges on achieving profitability and sustaining revenue growth amid high operational costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
